There are several studies that shows positive effect of incretins (Glucagon like peptide, GLP-1) and incretin receptor agonist (GLP1 receptor agonists) on cardiovascular risk factors in T2 DM [31–33], even in patients with chronic heart failure and left ventricular dysfunction who do not have diabetes [34, 35]. The gene discussed is GLP1R; the disease is congestive heart failure.